Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 17/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 8/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1439304 | 0.83 | CYP19A1 (0.50) | CYP19A1CYP17A1TDP1SCN1ASCN2A | |
| SCHEMBL11195088 | 0.81 | CYP19A1 (0.53) | CYP19A1CYP17A1TDP1SCN1ASCN2A | |
| SCHEMBL1439303 | 0.81 | CYP19A1 (0.48) | CYP19A1CYP17A1TDP1SCN1ASCN2A | |
| SCHEMBL4598002 | 0.79 | CYP19A1 (0.49) | CYP19A1CYP17A1TDP1SCN1ASCN2A | |
| SCHEMBL4597731 | 0.79 | CYP19A1 (0.49) | CYP19A1CYP17A1TDP1SCN1ASCN2A | |
| SCHEMBL17213197 | 0.79 | CYP19A1 (0.49) | CYP19A1CYP17A1TDP1SCN1ASCN2A | |
| SCHEMBL17213209 | 0.79 | CYP19A1 (0.49) | CYP19A1CYP17A1TDP1SCN1ASCN2A | |
| SCHEMBL4585582 | 0.77 | CYP19A1 (0.41) | CYP19A1CYP17A1TDP1SCN1ASCN2A | |
| SCHEMBL6404865 | 0.76 | CYP19A1 (0.59) | CYP19A1CYP17A1TDP1SCN1ASCN2A | |
| SCHEMBL19050813 | 0.74 | CYP19A1 (0.61) | CYP19A1CYP17A1TDP1SCN1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | claimed |
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | HUNTER-FLEMING LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| EP-1848426-B1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER FLEMING LTD (GB) | 2012-08-01 | — | — | EP | disclosed |
| EP-2097079-B1 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER FLEMING LTD (GB) | 2012-06-27 | — | — | EP | disclosed |
| WO-2008065408-A9 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER-FLEMING LIMITED (GB) | 2011-03-03 | — | — | WO | disclosed |
| US-20100137270-A1 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER-FLEMING LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| EP-2147673-A1 | Modulation of prostaglandin/cyclooxygenase metabolic pathways | Hunter-Fleming Limited (GB) | 2010-01-27 | — | — | EP | disclosed |
| US-20090259043-A1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER-FLEMING LIMITED (GB) | 2009-10-15 | — | — | US | disclosed |
| EP-2097079-A2 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | Hunter-Fleming Limited (GB) | 2009-09-09 | — | — | EP | disclosed |
| US-20080146644-A1 | Tricyclic Cytoprotective Compounds | HUNTER-FLEMING LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| EP-0570245-A2 | Octahydronaphthalene oxime derivatives for cholesterol biosynthesis inhibition, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1993-11-18 | — | — | EP | disclosed |
| EP-0560613-A1 | Antimicrobial carbapenem derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1993-09-15 | — | — | EP | disclosed |
| US-5242914-A | 2-(heterocyclylthio) carbapenem derivatives, their preparation and their use as antibiotics | SANKYO COMPANY, LIMITED (JP) | 1993-09-07 | — | — | US | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
| EP-0518558-A1 | 1-Methylcarbapenem derivatives, their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1992-12-16 | — | — | EP | disclosed |
| US-5104867-A | 2-(HETEROCYCLYLTHIO)CARBAPENEM DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ANTIBIOTICS | SANKYO COMPANY, LIMITED (JP) | 1992-04-14 | — | — | US | disclosed |
| EP-0470686-A2 | (Benzhydryloxyethylpiperidyl)aliphatic acid derivatives and their use in the treatment of allergies and asthma | Sankyo Company Limited (JP) | 1992-02-12 | — | — | EP | disclosed |
| EP-0437016-A2 | Lipid A analogues having immunoactivating and anti-tumour activity | Sankyo Company Limited (JP) | 1991-07-17 | — | — | EP | disclosed |
| EP-0363223-A2 | 3-Aryloxymethyl-cephalosporin derivatives, their preparation and their medical use | Sankyo Company Limited (JP) | 1990-04-11 | — | — | EP | disclosed |
| EP-0337637-A1 | 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146644-A1 | Tricyclic Cytoprotective Compounds | HCRTR1, CDR2, MSR1 | CYP19A1 3730/4885CYP17A1 3990/4885TDP1 2718/4885 |
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | PTGES2, PTGES, PTGS2 | CYP19A1 1369/4885CYP17A1 1843/4885TDP1 3064/4885 |
| US-20100137270-A1 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | PTGES2, PTGES, PTGS2 | CYP19A1 1369/4885CYP17A1 1843/4885TDP1 3064/4885 |
| US-20090259043-A1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HCRTR1, CDR2, MSR1 | CYP19A1 3730/4885CYP17A1 3990/4885TDP1 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.